Sana Biotechnology, Inc. (SANA) Stock Score, Valuation & Financial Research

Sana Biotechnology, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SANA

Sana Biotechnology, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.75. These figures are a research snapshot, not a buy or sell recommendation.

What Sana Biotechnology, Inc. does

Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Sana Biotechnology is a preclinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on developing engineered cell medicines, and it relies on raising capital through equity offerings and potential future collaborations to fund its research and development activities.

Products and services

  • The company is developing a pipeline of in vivo and ex vivo cell engineering programs, including candidates like UP421 for islet cell therapy and various fusosome-based delivery technologies.

Customer types

Clinical trial investigators and research institutions.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are unnamed. Source

Business strengths to evaluate

  • Proprietary fusogen technology for cell-specific delivery Source

Business risks and research considerations

  • History of significant losses and expectation of future losses Source
  • Pending securities class action litigation Source
  • Dependence on third-party manufacturing and clinical trial sites Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SANA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.75
Market capitalization:
765.3M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -211.82M
Free cash flow:
USD -144.77M
Cash:
USD 57.07M
Total debt:
USD 73.74M
EPS:
USD -0.76

What stands out

  • Free cash flow is USD -144.77M, negative for the stored period.
  • The balance sheet shows USD 57.07M of cash versus USD 73.74M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 16.67M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SANA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SANA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does SANA's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for SANA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SANA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SANA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.